Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 [The L-dihydroxyphenylalanine (L-DOPA) effect in Parkinson's syndrome in man: On the pathogenesis and treatment of Parkinson akinesis].

Literature DB >> 13971142

[The L-dihydroxyphenylalanine (L-DOPA) effect in Parkinson's syndrome in man: On the pathogenesis and treatment of Parkinson akinesis].

W BIRKMAYER, O HORNYKIEWICZ.

Abstract

Entities: Chemical Disease Species

Keywords: DOPA; MONOAMINE OXIDASE INHIBITORS; PARALYSIS AGITANS

Mesh：

Substances：

Year: 1962 PMID： 13971142 DOI： 10.1007/BF00343235

Source DB: PubMed Journal: Arch Psychiatr Nervenkr Z Gesamte Neurol Psychiatr

× No keyword cloud information.

25 in total

1. [Behavior of monoamine oxidase in the brain of man after therapy with monoamine oxidase inhibitors].

Authors: H BERNHEIMER; W BIRKMAYER; O HORNYKIEWICZ
Journal: Wien Klin Wochenschr Date: 1962-08-17 Impact factor: 1.704

2. The action of antidecarboxylases on the conversion of 3,4-dihydroxyphenylalanine to dopamine in vivo.

Authors: G F MURPHY; T L SOURKES
Journal: Arch Biochem Biophys Date: 1961-05 Impact factor: 4.013

3. [Inhibition of serotonin formation by alpha-methyl-DOPA].

Authors: E WESTERMANN; H BALZER; J KNELL
Journal: Naunyn Schmiedebergs Arch Exp Pathol Pharmakol Date: 1958

4. Drug-induced extrapyramidal reactions. Treatment with diphenhydramine hydrochloride and dihydroxyphenylalanine.

Authors: P L MCGEER; J E BOULDING; W C GIBSON; R G FOULKES
Journal: JAMA Date: 1961-09-09 Impact factor: 56.272

5. Occurrence and distribution of dopamine in brain and other tissues.

Authors: A BERTLER; E ROSENGREN
Journal: Experientia Date: 1959-01-15

6. [Nerve tissue DOPA decarboxylase and histidine decarboxylase].

Authors: P HOLTZ; E WESTERMANN
Journal: Naunyn Schmiedebergs Arch Exp Pathol Pharmakol Date: 1956

7. Serotonin as a mediator of reserpine action in brain.

Authors: A PLETSCHER; P A SHORE; B B BRODIE
Journal: J Pharmacol Exp Ther Date: 1956-01 Impact factor: 4.030

8. Enzymatic decarboxylation of isomers and derivatives of dihydroxyphenylalanine.

Authors: T SOURKES; P HENEAGE; Y TRANO
Journal: Arch Biochem Biophys Date: 1952-09 Impact factor: 4.013

9. [The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia].

Authors: W BIRKMAYER; O HORNYKIEWICZ
Journal: Wien Klin Wochenschr Date: 1961-11-10 Impact factor: 1.704

10. Excretion of dopamine in diseases of basal ganglia.

Authors: A BARBEAU; G F MURPHY; T L SOURKES
Journal: Science Date: 1961-05-26 Impact factor: 47.728

44 in total

1. [THE EFFICACY OF L-DOPA IN PARKINSON PATIENTS WITH AND WITHOUT STEREOTACTIC BRAIN SURGERY].

Authors: W UMBACH; D BAUMANN
Journal: Arch Psychiatr Nervenkr Date: 1964-06-01

2. [ADDITIONAL EXPERIMENTAL STUDIES ON L-DOPA IN PARKINSON'S SYNDROME AND RESERPINE PARKINSONISM].

Authors: W BIRKMAYER; O HORNYKIEWICZ
Journal: Arch Psychiatr Nervenkr Date: 1964-12-02

3. [AUTONOMIC REGULATION DISTURBANCES IN PATIENTS RECOVERING FROM ENCEPHALITIS].

Authors: W BIRKMAYER
Journal: Acta Neuroveg (Wien) Date: 1964-10-02

4. Biochemical mechanisms and management of choreiform movement disorders.

Authors: L de Silva
Journal: Drugs Date: 1977-10 Impact factor: 9.546

Review 5. Substantia nigra hyperechogenicity is a risk marker of Parkinson's disease: no.

Authors: Uwe Walter
Journal: J Neural Transm (Vienna) Date: 2010-12-29 Impact factor: 3.575

Review 6. Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs.

Authors: Delphine Charvin; Rossella Medori; Robert A Hauser; Olivier Rascol
Journal: Nat Rev Drug Discov Date: 2018-09-28 Impact factor: 84.694

7. Selective inhibition of monoamine oxidase type B by MDL 72145 increases the central effects of L-dopa without modifying its cardiovascular effects.

Authors: J R Fozard; M G Palfreyman; M Robin; M Zreika
Journal: Br J Pharmacol Date: 1986-01 Impact factor: 8.739